Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575490 | 0.86 | L3MBTL1 (0.48) | L3MBTL1POLBKDM4EGAAALDH1A1 | |
| SCHEMBL1575013 | 0.84 | L3MBTL1 (0.49) | L3MBTL1POLBKDM4EGAAALDH1A1 | |
| SCHEMBL1575152 | 0.84 | L3MBTL1 (0.49) | L3MBTL1POLBKDM4EGAAALDH1A1 | |
| SCHEMBL1575211 | 0.82 | KMT2A (0.47) | ALDH1A1SMN1; SMN2HSD17B10TSHRRAB9A | |
| SCHEMBL1574970 | 0.79 | LMNA (0.43) | HSD17B10NAMPT | |
| SCHEMBL1575454 | 0.79 | GAA (0.33) | L3MBTL1GAAALDH1A1EPHX2MAPT | |
| SCHEMBL1575052 | 0.75 | NAMPT (0.46) | EPHX2NAMPT | |
| SCHEMBL1574434 | 0.73 | L3MBTL1 (0.59) | L3MBTL1POLBKDM4EALDH1A1MAPT | |
| SCHEMBL8254511 | 0.72 | L3MBTL1 (0.43) | L3MBTL1POLBKDM4EGAAALDH1A1 | |
| SCHEMBL1575168 | 0.72 | L3MBTL1 (0.56) | L3MBTL1POLBKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | L3MBTL1 3473/4885POLB 4641/4885KDM4E 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.